Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study

PharmacoEconomics
Martin KnappSOHO Study Group

Abstract

To determine the cost utility of treating schizophrenic patients with olanzapine compared with other antipsychotics in a naturalistic outpatient setting. The pan-European SOHO study is a 3-year, prospective, outpatient, observational study of outcomes associated with antipsychotic treatment, focusing on olanzapine, in ten European countries. For the cost-utility analysis, healthcare resource use (inpatient care, day care, outpatient psychiatric consultations and antipsychotic and concomitant medication use) and EQ-5D data were collected at baseline and at 3, 6 and 12 months. The perspective was that of the health service payer. UK healthcare unit costs (year 2004 values) were applied to the resource use data for the ten countries. UK population tariffs were applied to the EQ-5D data to determine utility values.An Epoch analysis was used to analyze the longitudinal data. Multivariate regression analyses that adjusted for baseline covariates were used to estimate the incremental cost and utility gains for patients treated with olanzapine compared with each of the other antipsychotics (risperidone, quetiapine, amisulpride, clozapine and oral or depot typical antipsychotics). A total of 10 972 patients were enrolled at baseline, of...Continue Reading

References

Jun 6, 1996·Health Policy·R Brooks
Jul 30, 1999·BMJ : British Medical Journal
Jul 27, 2001·Journal of Health Economics·W G Manning, J Mullahy
Jan 31, 2002·The Journal of Clinical Psychiatry·M LewisS Frangou
Jul 4, 2002·Psychiatric Services : a Journal of the American Psychiatric Association·Matthew A FullerMichael B Durkin
Feb 13, 2003·Acta Psychiatrica Scandinavica·J M HaroUNKNOWN SOHO Study Group
Apr 30, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·Matthew J ByerlyJason Hawkins
May 21, 2003·The Journal of Clinical Psychiatry·David M TaylorUNKNOWN Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS) U.K. Investigator Group
Dec 4, 2003·JAMA : the Journal of the American Medical Association·Robert RosenheckUNKNOWN Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine
Jan 15, 2004·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·P Joseph GibsonJanet L Ramsey
Sep 16, 2004·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Montserrat Vera-LlonchGerry Oster
Mar 11, 2005·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Patricia A RussoMadhav Namjoshi
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Feb 9, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·P LecomteU Persson
Sep 21, 2006·International Journal of Technology Assessment in Health Care·Frank WindmeijerJosep Maria Haro
Dec 8, 2006·The American Journal of Psychiatry·Robert A RosenheckUNKNOWN CATIE Study Investigators

❮ Previous
Next ❯

Citations

Sep 20, 2011·Epidemiology and Psychiatric Sciences·P McCrone
Aug 4, 2009·The British Journal of Psychiatry : the Journal of Mental Science·Garry R BartonDavid Fowler
Sep 6, 2013·Journal of Medical Economics·Thomas R Einarson, Michiel E H Hemels
Nov 29, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Esther W ChanDavid C M Kong
Nov 11, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jordi AlonsoDiego Novick
Feb 19, 2015·Health Technology Assessment : HTA·Karl ClaxtonMark Sculpher
Dec 21, 2017·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Lisanne I van LierHenriëtte G van der Roest
Jan 15, 2014·The Cochrane Database of Systematic Reviews·Kai KochVivek A Furtado
Nov 3, 2010·The British Journal of Psychiatry : the Journal of Mental Science·Samuli I SaarniJaana Suvisaari
May 4, 2010·The British Journal of Psychiatry : the Journal of Mental Science·Paul McCronePhilippa A Garety

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.